NASDAQ:INCY

Incyte Stock Forecast, Price & News

$81.76
+0.48 (+0.59 %)
(As of 05/6/2021 11:21 AM ET)
Add
Compare
Today's Range
$80.33
$82.29
50-Day Range
$78.25
$85.61
52-Week Range
$75.52
$110.36
Volume29,439 shs
Average Volume1.26 million shs
Market Capitalization$17.98 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.96
30 days | 90 days | 365 days | Advanced Chart
Receive INCY News and Ratings via Email

Sign-up to receive the latest news and ratings for Incyte and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:INCY
CUSIP45337C10
Phone302-498-6700
Employees1,773
Year Founded1991

Sales & Book Value

Annual Sales$2.16 billion
Cash Flow$2.21 per share
Book Value$12.06 per share

Profitability

Net Income$446.91 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap$17.98 billion
Next Earnings Date8/3/2021 (Estimated)
OptionableOptionable

Social Links


Headlines

See More Headlines
Incyte logo

About Incyte

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase III clinical trial to treat naïve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; and Cellenkos, Inc., as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

MarketRank

Overall MarketRank

1.65 out of 5 stars

Medical Sector

343rd out of 2,043 stocks

Commercial Physical Research Industry

7th out of 42 stocks

Analyst Opinion: 2.2Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Incyte (NASDAQ:INCY) Frequently Asked Questions

Is Incyte a buy right now?

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last twelve months. There are currently 1 sell rating, 8 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Incyte stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INCY, but not buy additional shares or sell existing shares.
View analyst ratings for Incyte
or view top-rated stocks.

What stocks does MarketBeat like better than Incyte?

Wall Street analysts have given Incyte a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Incyte wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Incyte?

Incyte saw a decline in short interest in the month of April. As of April 15th, there was short interest totaling 4,960,000 shares, a decline of 16.1% from the March 31st total of 5,910,000 shares. Based on an average daily trading volume, of 1,280,000 shares, the short-interest ratio is currently 3.9 days.
View Incyte's Short Interest
.

When is Incyte's next earnings date?

Incyte is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Incyte
.

How were Incyte's earnings last quarter?

Incyte Co. (NASDAQ:INCY) announced its quarterly earnings results on Tuesday, May, 4th. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.42 by $0.25. The biopharmaceutical company earned $604.72 million during the quarter, compared to analysts' expectations of $657.73 million. Incyte had a negative trailing twelve-month return on equity of 13.66% and a negative net margin of 13.62%. The firm's revenue was up 6.4% on a year-over-year basis. During the same quarter last year, the business posted ($2.86) EPS.
View Incyte's earnings history
.

How has Incyte's stock been impacted by Coronavirus (COVID-19)?

Incyte's stock was trading at $71.90 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, INCY shares have increased by 13.0% and is now trading at $81.28.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for INCY?

18 Wall Street analysts have issued 12 month price targets for Incyte's stock. Their forecasts range from $70.00 to $124.00. On average, they expect Incyte's share price to reach $100.77 in the next year. This suggests a possible upside of 24.0% from the stock's current price.
View analysts' price targets for Incyte
or view top-rated stocks among Wall Street analysts.

Who are Incyte's key executives?

Incyte's management team includes the following people:
  • Mr. Herve Hoppenot, Chairman, Pres & CEO (Age 61, Pay $2.47M)
  • Ms. Christiana Stamoulis, Exec. VP & CFO (Age 50, Pay $1.2M)
  • Dr. Wenqing Yao, Exec. VP & Head of Discovery Chemistry (Age 58, Pay $847.81k)
  • Dr. Barry P. Flannelly M.B.A., Pharm.D., MBA, Exec. VP & GM of North America (Age 63, Pay $803.14k)
  • Dr. Steven H. Stein, Exec. VP & Chief Medical Officer (Age 54, Pay $937.73k)
  • Mr. Michael James Morrissey, Exec. VP & Head of Global Technical Operations (Age 57)
  • Dr. Dashyant Dhanak Ph.D., Exec. VP & Chief Scientific Officer (Age 60)
  • Mr. Michael Booth DPhil, Divisional VP of Investor Relations & Corp. Social Responsibility (Age 50)
  • Ms. Christine Chiou, Head of Investor Relations
  • Ms. Maria E. Pasquale, Exec. VP & Gen. Counsel (Age 55)

What is Hervé Hoppenot's approval rating as Incyte's CEO?

22 employees have rated Incyte CEO Hervé Hoppenot on Glassdoor.com. Hervé Hoppenot has an approval rating of 80% among Incyte's employees.

Who are some of Incyte's key competitors?

What other stocks do shareholders of Incyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), (KITE) (KITE), Freeport-McMoRan (FCX) and NVIDIA (NVDA).

What is Incyte's stock symbol?

Incyte trades on the NASDAQ under the ticker symbol "INCY."

Who are Incyte's major shareholders?

Incyte's stock is owned by a number of institutional and retail investors. Top institutional shareholders include The Manufacturers Life Insurance Company (0.69%), Sumitomo Mitsui Trust Holdings Inc. (0.41%), Manning & Napier Group LLC (0.23%), Assenagon Asset Management S.A. (0.22%), Country Trust Bank (0.17%) and NN Investment Partners Holdings N.V. (0.12%). Company insiders that own Incyte stock include Barry P Flannelly, Bros Advisors Lp Baker, Dashyant Dhanak, Herve Hoppenot, Jean Jacques Bienaime, Jonathan Elliott Dickinson, Maria E Pasquale, Michael James Morrissey, Paul A Friedman, Paul Trower, Paula J Swain, Steven H Stein, Wendy L Dixon and Yao Wenqing.
View institutional ownership trends for Incyte
.

Which major investors are selling Incyte stock?

INCY stock was sold by a variety of institutional investors in the last quarter, including Robeco Institutional Asset Management B.V., Assenagon Asset Management S.A., US Bancorp DE, Strs Ohio, NN Investment Partners Holdings N.V., M&T Bank Corp, Sentry Investment Management LLC, and Chevy Chase Trust Holdings Inc.. Company insiders that have sold Incyte company stock in the last year include Dashyant Dhanak, Herve Hoppenot, Jonathan Elliott Dickinson, Maria E Pasquale, Michael James Morrissey, Paul Trower, Steven H Stein, and Yao Wenqing.
View insider buying and selling activity for Incyte
or view top insider-selling stocks.

Which major investors are buying Incyte stock?

INCY stock was acquired by a variety of institutional investors in the last quarter, including Virginia Retirement Systems ET AL, PGGM Investments, Country Trust Bank, Seizert Capital Partners LLC, Sumitomo Mitsui Trust Holdings Inc., The Manufacturers Life Insurance Company , DnB Asset Management AS, and Great Lakes Advisors LLC. Company insiders that have bought Incyte stock in the last two years include Bros Advisors Lp Baker, and Herve Hoppenot.
View insider buying and selling activity for Incyte
or or view top insider-buying stocks.

How do I buy shares of Incyte?

Shares of INCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Incyte's stock price today?

One share of INCY stock can currently be purchased for approximately $81.28.

How much money does Incyte make?

Incyte has a market capitalization of $17.87 billion and generates $2.16 billion in revenue each year. The biopharmaceutical company earns $446.91 million in net income (profit) each year or $2.23 on an earnings per share basis.

How many employees does Incyte have?

Incyte employs 1,773 workers across the globe.

When was Incyte founded?

Incyte was founded in 1991.

What is Incyte's official website?

The official website for Incyte is www.incyte.com.

Where are Incyte's headquarters?

Incyte is headquartered at 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803.

How can I contact Incyte?

Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company can be reached via phone at 302-498-6700 or via email at [email protected]


This page was last updated on 5/6/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.